1-2 of 2
Jianhua Jin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Plamotamab Combined with Tafasitamab (Tafa) + Lenalidomide (Len) Vs Tafa+Len in Relapsed or Refractory DLBCL

Krish Patel, Youngil Koh, Sabarish Ayyappan, Yasmin Karimi, Izidore S. Lossos, Akil Merchant, Phuong Lee, Jianhua Jin, Raphael Clynes, Jitendra Kanodia, Michael T. Chiarella, Steve Kye, Jean-Marie Michot
Journal: Blood
Blood (2022) 140 (Supplement 1): 12066–12067.
https://doi.org/10.1182/blood-2022-158042
Published: 2022
Journal Articles

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Krish Patel, Peter A. Riedell, Hervé Tilly, Sairah Ahmed, Jean-Marie Michot, Herve Ghesquieres, Jean Marc Schiano de Collela, Asher Chanan-Khan, Kamal Bouabdallah, Benoit Tessoulin, Sunil Iyengar, Meixiao Long, Raphael Clynes, Jitendra Kanodia, Lei Bao, Ying Ding, Jianhua Jin, William B Ainsworth, Raman Garcha, Steve Kye, Tycel J. Phillips
Journal: Blood
Blood (2022) 140 (Supplement 1): 9470–9472.
https://doi.org/10.1182/blood-2022-159586
Published: 2022